🇺🇸 KRYS — Krystal Biotech, Inc.

Nombre completo

Krystal Biotech, Inc.

Divisa

USD

Mercado

NasdaqGS

Sector

Salud

Industria

Biotechnology

Empleados

295

PER ⓘ

41,44 (puede no estar actualizado)

Dividend yield

0,00% (puede no estar actualizado)

Precio objetivo analistas

393,56 USD (puede no estar actualizado)

Primera cotización

20/09/2017

Precio actualizado

hace 9 horas

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.